Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 1, 2006, Pages 23-38

  Robak, Tadeusz ^a   Korycka, Anna ^a   Robak, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute myeloid leukemia; Cladribine; Langerhans cell histiocytosis; Leukemia; Lymphoma; Oral; Pharmacokinetics; Subcutaneous; Systemic mastocytosis

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE;

ANIMAL; BLOOD DISEASE; CHEMISTRY; DRUG INTERACTION; HUMAN; PATENT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CLADRIBINE; DRUG INTERACTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; PATENTS AS TOPIC;

EID: 39049106629     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206775246467     Document Type: Review

References (150)

1. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: Pharmacology and clinical applications. Curr Cancer Drug Targets 2005; 5:421-44
2. Bryson HM, Sorkin EM. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993; 76: 872-94.
3. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980; 77: 6865-69.
4. Kazimierczuk Z, Cottam HB, Revankar GR, Robins RK. Synthesis of 2-deoxynucleosides via a novel direct sterospecific sodium salt glycocylation procedure. J Am Chem Soc. 1984; 106: 6379-82.
5. Carson DA, Kay J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase. Proc Natl Acad Sci USA 1977; 74: 5677-81.
6. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6.
7. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukemia. Leukemia 2004; 18: 385-93.
8. Molina-Arcas M, Marce S, Villamor N. Equilibrqtive nucleoside transporter 2-(hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005; 19: 64-8.
9. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-43.
10. Avery TL, Regh JE, Lumm WC, Harwood FC, Santana VN, Blakley RL. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 1989; 49: 4972-8.
11. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377-83.
12. Griffig J, Koob R, Blakley RL. Mechanism of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989; 49: 6923-28.
13. Warzocha K, Fabianowska-Majewska K, Blonski J, Krykowski E, Robak T. 2-chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukemia. Eur J Cancer 1997; 33: 170-3.
14. Robertson LE, Chubb S, Meyn RE, et al. W. Induction of apoptotic cell death in chronic lymphocytic leukemia 2-chloro-2́-deoxy-adenosine and 9-d-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-50.
15. Castejon R, Vargas JA, Briz M, et al. Induction of apoptosis by 2-chlorodeoxyadenosine in B-cell chronic lymphocytic leukemia. Leukemia 1997; 11: 1253-1257.
16. Pettit AR. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br J Haematol 2003; 121: 692-702.
17. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytydine kinase and cytoplasmic 5ńucloetidase to the chemothrapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597-601.
18. Carson DA, Carrera CJ, Wasson DB, Yamanaka H. Proogrammed cell death and adenine deoxynucleotide metabolism in humans lymphocytes. Adv Enzyme Regul 1988; 27, 395-404.
19. Genini D, Adachi S, Chao O, et al. Deoxyadenosine analogues induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000: 96, 3537-43.
20. Marzo I, Perez-Gala P, Rubio-Felix D, Anel A, Naval J. Cladribine induces apoptosis in human leukemia cells by caspasedependent and-independent pathways acting on mitochondria. Biochemistry 2001, 359: 537-46.
21. Nomura Y, Inanami O, Takahashi K, Matsuda A, Kuwabara M. 2-Chloro-2́-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. Leukemia 2000; 14: 299-306.
22. Klopfer A, Hasenjager A, Belka C, Schulze-Osthoff K, Dorken B, Daniel, P. Adenine deoxynucleotides fludarabine and cladribine induces apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene 2004; 16: 9408-18.
23. Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chlorodeoxyadenosine. Proc Natl Acad Sci USA 1984; 81: 2232-36.
24. Johnson SA. Clinical pharmacokinetics of nucleoside analogues. Focus on haematological malignancies. Clin Pharmacokinet 2000; 39: 5-26.
25. Beutler E, Piro LD, Saven A, et al. 2-Chlorodeoxyadenosine (2-CdA). A potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 1991; 5: 1-8.
26. Saven A, Cheung WK, Smih I, et al. Pharmacokinetics study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14: 978-83.
27. Liliemark J, Albertioni F, Hassan M, et al. One the bioavailability of oral and subcutaneous 2-chloro-2́-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol. 1992; 10: 1514-8.
28. Liliemark J. and Juliusson G. On the pharmacokinetics of 2-chloro-2́-deoxyadenosine in humans. Cancer Res 1991; 51: 5570-2.
29. Albertioni F, Petterson B, Reichalova V, et al. Analysis of 2-chloro-2́-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography. Ther Drug Monit 1995; 16: 413-8.
30. Santana VN, Mirro J Jr, Harwood FC, et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991; 9: 416-22.
31. Lindemalm S, Savic RM, Karlsson MO, Liliemark J, Juliusson G, Albertioni F. Application of population pharmacokinetics to cladribine. BMC Pharmacology 2005; 5: 4.
32. Liliemark J, Pettersson B, Juliusson G. Determination of 2-chloro-2́-deoxyadenosine in human plasma. Biomed Chromatogr 1991; 5: 262-4.
33. Santana VM, Mirro Jr. J, Kearns C, Schell MJ, Crom W. Blakley R. L 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10: 364-70.
34. Schultz, T.W., Naeff, R.: US6194395 (2001).
35. Bodor, N.S., Dandiker, Y.: WO04087101A3 (2004).
36. Wrenn, Jr.S.M.: US6174873 (2001).
37. Lauria F, Boachia M, Marrotta G, Respadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84: 22-5.
38. Robak T, Kasznicki M, Góra-Tybor J, et al. Randomized comparison of weekly administration and daily courses of cladribine in patients with hairy cell leukemia. Updated results. Blood 2004; 104 (suppl. 1): 948a (abstract 3478).
39. Albertioni F, Juliusson G, Liliemark J. On the bioavailability of 2-chloro-2́-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 1993; 44: 579-82.
40. Albertioni F, Juliusson G, Liliemark J. On the pharmacokinetics of 2-chloro-deoxyadenosine (CdA) and renal excretion after intravenous and oral administration. Proc. Am Soc Clin Oncol Ann Meet 1994; 13, A421 (abstract).
41. Albertioni F, Lindemalm S, Reichelova V, et al. Pharmacokinetics of cladribine in plasma and its 5́-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 1998; 4: 653-58.
42. Arner ES, Spasokoukotskaja T, Juliusson G, Liliemark J, Eriksson S. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. Br J Haematol 1994; 87: 715-8.
43. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5́-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597-601.
44. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-a-arabinosyl-2-fluoroadenine in chronic lymphocytoc leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875-81.
45. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-95.
46. Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001; 40; 551-64
47. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-9.
48. Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia treated with cladribine Eur J Cancer 2004; 40: 383-9.
49. Begleiter A, Wang H, Verburg L, et al. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996; 10: 1959-65.
50. Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, Robak T. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002; 68: 370-5.
51. Szmigielska-Kaplon A, Smolewski P, Najder M, Robak T. Evaluation of apoptosis induced in vitro by cladribine (2-CDA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Ann Hematol 2002; 81: 508-13.
52. Robak T, Szmigielska A. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemia L1210 and P388. Neoplasma 2000; 47: 168-71.
53. Chow KU, Boehrer S, Napieralski S, et al. In AML cell lines Ara-C combined with purine nucleoside analogues is able to exert synergisitic as well antaginistic effects on proliferation and disruption of mitochondrial membrane potential. Leuk. Lymphoma 2003; 44: 165-173.
54. Kristensen J, Nygren P, Liliemark J, et al. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 1992; 8: 1712-7.
55. Schirmer M, Geisen F, Tiefenthalter M, Konwalinka G. Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia. Leuk Res 1999; 23: 1121-6.
56. Maranda E, Szmigielska A, Robak T. Additive action of gemcitabine (2́,2́-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. Cancer Invest 1999; 17: 95-101.
57. Robak T, Korycka A. The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with i interferon (IFN and interferon)(IFN on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in cultures in vitro. Leuk Lymphoma 1996; 21: 161-8.
58. Korycka A, Robak T. The influence of imatinib mesylate (STI571) used alone or in combination with purine analogues on the normal and chronic myelogenous leukemia progenitor cells in vitro. Leuk Lymphoma 2003, 44, 1549-55.
59. Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogues on acute myeloid leukemia progenitors in vitro. Eur J Haematol 2004; 73: 418-26.
60. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma 2005; 46: 87-100.
61. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadensine. N. Engl J Med 1990; 322:1117-21
62. Chadha P, Rademaker AW, Mendirata P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106: 241-6
63. Cheson BD, Sorensen JM, Vena DA. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group Protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007-15.
64. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia phenotype of hairy cell and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672-81.
65. Robak T, Blasinska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996; 22: 107-11.
66. von Rohr A, Schmitz SF, Tichelli A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13: 1641-9.
67. Tallman MS, Zakarija A. Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease. Transfus Apheresis Sci 2005; 32: 99-103.
68. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476-81.
69. + lymphocytopenia after treatment. Leuk Lymphoma 1999; 35: 555-65.
70. Zinzani PL, Magagnoli M, Bandandi M, et al. Long-term followup of hairy cell leukemia patients treated with 2-chlorodoexyadenosine. Haematologica 2000; 85: 922-5.
71. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891-6.
72. Tallman MS, Hakkimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-9.
73. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine: Response, toxicity and long-term folowup. J Clin Oncol 1997; 15: 1138-42.
74. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8: 1153-16.
75. Robak T, Blasinska-Morawiec M, Blonski J, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant 7-year experience in Poland. Eur J Haematol 1999; 62: 49-56.
76. Saven A, Burian C, Koziol JA, Piro LD. Long term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-26.
77. Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2́-deoxycoformycin. Ann Intern Med 1993; 119: 278-3.
78. Piro LD, Carera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 71: 1069-73.
79. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015-27.
80. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia: updated results of the multicenter study of 378 patients. Br Haematol 2000; 108: 357-68
81. Karlson K, Stromberg N, Jonsson V. Cladribine (CdA), fludarabine (F) or high-dose intermitten chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia. First interim analysis of data from the international randomized phase III trial. Blood 2004; 104 (suppl 1): 945 (abstract 3470).
82. Robak T, Blonski JZ, Góra-Tybor J, et al. Cladribine with cyclophosphamide v.s. fludarabine with cyclophosphamide as first line treatment in chronic lymphocytic leukemia an early report of prospective randomized study (PALG CLL3). Hematologica Hematology J 2005; 90; 143 (abstract 364)
83. Montilo M, Tedeschi A, P'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114-20.
84. Robak T, Blonski JZ, Kasznicki M et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3: 244-50.
85. Robak T, Góra-Tybor J, Lech-Maranda E, Blonski JZ, Kasznicki M. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Hematol 2001; 66: 188-94.
86. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front line therapy in chronic lymphocytic leukemia. Leukemia 2001; 15: 1510-6.
87. Robak T, Blonski JZ, Góra-Tybor J, et al. Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study. Blood 2004; 104 (suppl 1): 100a (abstract 337).
88. Smolewski P, Szmigielska A, Cebula B, Sobczak A, Darzynkiewicz Z, Robak T. Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in BCLL chronic lymphocytic leukemia cells measured by fluorochrome labeled inhibitors of caspases (FLICA) assay. Blood 2002; 100: (suppl 1). 387a (abstract 1503).
89. Robak T, Smolewski P, Urbanska-Rys H, Góra-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004; 45: 937-44.
90. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160-6.
91. Karlson K, Stromberg N, Liliemark J, et al. Oral cladribine for Bcell chronic lymphocytic leukemia: report of a phase II trial with a 3-4, 3 weekly schedule in untreated and pretreated patients and a long-term follow up of 126 previously treated patients. Br J Hematol 2002; 116: 538-48.
92. Betticher DC, Ratschiller D, Hsu SF, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol 1998; 9: 721-6.
93. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118: 195-8.
94. Dimopoulos MA, Kantarjian H, Wela D, et al. Primary therapy of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12: 2694-8.
95. Dimopoulos MA, Weber DN, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6: 49-52.
96. Delannoy A, Van den Nesste E, Michaux JL, Bosly A, Ferrant A. Cladribine for Waldenstrom's macroglobulinemia. Br J Haematol 1999; 104: 928-36.
97. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. Cladribine (2-CdA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinemia. Br J Haematol 1997; 99: 358-363.
98. Liu ES, Burian C, Miller HE, et al. Bolus administration of cladribine in the treatment of Waldenström macroglobulinemia. Br J Haematol 1998; 103: 690-5.
99. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol 1999; 63: 35-41.
100. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol 2003; 30:243-7
101. Dimopoulos M, Mertim G, Leblond A, Anagnostopoulos A, Alexanian R. How we treat Waldenström's macroglobulinemia. Haematologica Hematology J 2005; 90: 117-25.
102. Johnson SA, Oscier DG, Leblond V. Waldenström's macroglobuli-nemia. Blood Rev 2002; 16: 175-84.
103. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade non-Hodgkin's lymphomas. J Clin Oncol 1992; 10: 371-7.
104. Betticher DC, Fey MF, von Rohr A, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphoma and chronic and acute leukemias. Ann Oncol 1994; 5: 57-64.
105. Liliemark J, Porwit A, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 25: 313-8.
106. Armitage JO, Tobinai K, Hoelzer D, Rummel J. Treatment of indolent non-Hodgin's lymphoma with cladribine as single agent therapy and in combination with mitoxantrone. Int J Hematol 2004; 79: 311-21.
107. Hoffman M, Tallman MS, Hakimian D, et al. 2-chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 788-92.
108. Robak T, Góra-Tybor J, Krykowski E, et al. Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26: 99-105.
109. Ogura M, Morishina Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 2004; 80: 267-77.
110. Zinzani PL. Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002; 15: 505-16.
111. Pott-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6:421-33.
112. Saven A, Emanuele S, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710-6.
113. Rummel MJ, Chow KU, Jager E, et al. Intermittent 2-hourinfusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma 1999; 35:129-38.
114. Canfield VA, Vose J, Guiney P, et al. 2-Chlorodeoxyadenosine as initial therapy for advanced low-grade non-Hodgkin's lymphomas. Leuk Lymphoma 1997; 24: 335-9.
115. Fridrik M, Linkesch W, Jager G, et al. Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine)-2-h infusion for 5 days-as first-line treatment for advanced low-grade non-Hodgkin's lymphoma. Eur J Cancer 1998; 34: 1560-64.
116. Liliemark J, Martinsson U, Cavalln-Stahl E, et al. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1998; 30: 573-81.
117. Laurencet FM, Zulian GB, Guetty-Alberto, M, et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative nalignancies. Br J Cancer 1999; 79: 1215-9.
118. Robak T, Góra-Tybor J, Urbanska-Rys H, et al. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low-grade non-Hodkin's lymphoma. Leuk Lymphoma 1999; 32: 359-368.
119. Van den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-2-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000; 14: 1136-42.
120. Robak T, Szmigielska-Kaplon A, Blonski JZ, Kasznicki M, Chojnowski K. Activity of combined cladribine with etoposide in heavily pretreated patients with indolent lymphoid malignancies. Chemotherapy 2005; 51: 247-51.
121. Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M. Low dose 2-CdA schedule activity in splenic marginal zone lymphoma. Hematol Oncol 2002; 21: 163-8
122. Rummel MJ, Chow KU, Karahas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002; 38: 1739-46
123. Kong LR, Samuelson E, Rosen ST. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma 1997; 26: 89-97.
124. Bouwhuis SA, El-Azhary RA, McEvoy MT, et al. Treatment of late-stage Sezary syndrome with 2-chlorodeoxyadenosine. Int J Dermatol 2002; 41: 352-6.
125. Tobinai K, Uike N, Saburi Y, Chou T, et al. Cladribine/ATL Study Group, Japan. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemialymphoma. Int J Hematol 2003; 77: 512-7.
126. Saven A, Figueroa ML, Piro LD, Rosenblatt JD. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med 1993; 329: 734-5.
127. Saven A, Foon KA, Piro D. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans cell histiocytosis. Ann Intern Med 1994; 121: 430-2.
128. Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood 1999; 93: 4125-30.
129. Weitman S, Wayne A, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999; 33: 476-81.
130. Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003; 78: 301-6.
131. Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL. Efficacy of continuous infusion 2-CdA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43: 81-4.
132. Robak T, Kordek P, Robak E, et al. Langerhans cell histiocytosis in a patient with systemic lupus erythematosus a clonal disease responding to treatment with cladribine and cyclophosphamide. Leuk Lymphoma 2002; 43: 2041-46.
133. Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84: 1237-42.
134. Van den Neste E, Martiat P, Mineur P, et al. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann Hematol 1998; 76: 19-23.
135. Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996; 10: 1563-1569.
136. Gordon MS, Young ML, Tallman MD, et al. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res 2000; 24: 871-5.
137. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic disease. J Clin Oncol 2001; 19: 2804-11.
138. Vahdat L, Wong E, Wile M, Rosenblum M, Foley KM, Warell Jr. RP. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeleoid leukemia. Blood 1994; 84: 3429-34.
139. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood 1996; 87: 256-64.
140. Robak T, Wrzesien-Kus A, Lech-Maranda E, Kowal M, Dmoszynska A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2000; 39: 121-9.
141. Wrzesien-Kus A, Robak T, Wierzbowska A, et al. A multicenter open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 2005; 84: 557-64
142. Juliusson G, Liliemark J. 2-Chlorodeoxyadenosine (CDA) with and without cytosine arabinoside (Ara-C) and idarubicin for acute myeloid and lymphoid leukemia-clinical and pharmacokinetic studies. Br J Haematol 1994; 87: 48a (Abstract)
143. Juliusson G, Lofgren C, Mollgard L, et al. No additional toxicity from cladribine (CdA) as primary treatment of acute myeloid leukemia in elderly patients: results from a randomized phase II study from the Leukemia Group of Middle Sweden (LGMS) Blood 2001; 98 (suppl 1): 123a (abstract 518).
144. Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter phase III study. Leukemia 2004; 18: 989-97.
145. Samorapoompichit P, Steiner M, Lucas T, et al. Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. Leuk Lymphoma 2003; 44: 509-15.
146. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast cell disease with cladribine. N Engl J Med 2001; 344: 307-9.
147. Pardanami A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127-31.
148. Kluin-Nelemans HC, Oldhoff JM, van Doormoal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-6.
149. Wrzesien-Kus A, Robak T, Lech-Maranda E, et al. Polish Adult Leukemia Group. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF as induction therapy in refractory acute myeloid leukemia-a report of the Polish Adult Leukemia Group (PALG) Eur J Haematol 2003; 71: 155-62.
150. Kearns CM, Blakley RL, Santana VM, Crom W. Pharmacokinetics of cladribine (2-chlorodeoxyadenine) in children with acute leukemia. Cancer Res 1994; 54: 1235-9.